REPORT FROM THE 9th INTERNATIONAL CONFERENCE AD/PD, PRAGUE, CZECH REPUBLIC, MARCH 11-15, 2009 – The Sydney Multicentre Study of Parkinsons disease was initially a prospective 5-year trial comparing low-dose bromocriptine (< 30 mg/day) and low-dose levodopa-carbidopa (< 600/150 mg/day) in 149 previously untreated patients (mean age 62 years) with Parkinsons disease (Hely et al. Med J Aust 1987;146:195-198).
Participants were recruited between 1984 and 1987. Those subjects have now been followed for 20 years; assessments have included periodic neuropsychological testing at baseline and years 3, 5, 10, 15 and 20.